Results 241 to 250 of about 176,720 (311)

Early Pregnancy Waist Circumference for Prediction of Fetal Macrosomia. [PDF]

open access: yesReprod Sci
Junus K   +5 more
europepmc   +1 more source

Unveiling the BMI Risk Threshold for Osteoarthritis: Multi‐Database Causal and Nonlinear Evidence

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To characterize the nonlinear relationship between BMI and osteoarthritis (OA), and to identify BMI thresholds that inform precise prevention strategies. Methods This multi‐database study integrated Global burden of disease 2021, National Health and Nutrition Examination Survey 2007–2018, and Genome‐Wide Association Studies.
Shaohong Yu   +9 more
wiley   +1 more source

Comparing waist circumference with body mass index on obesity-related cancer risk: a pooled Swedish study. [PDF]

open access: yesJ Natl Cancer Inst
Sun M   +16 more
europepmc   +1 more source

Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Access to kidney transplantation (KTx) for people living with obesity and kidney failure is often challenging, especially given the inconsistent availability of publicly funded obesity services across the United Kingdom. This study explored UK kidney healthcare providers' views on weight management support for patients with obesity on ...
Adrian Brown   +9 more
wiley   +1 more source

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin   +6 more
wiley   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey   +4 more
wiley   +1 more source

Comparative analysis of sarcopenic obesity detection and associated mental-cognitive outcomes in community-dwelling older adults: impact of using body mass index versus waist circumference. [PDF]

open access: yesBMC Geriatr
Dong P   +16 more
europepmc   +1 more source

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m2 and at least one obesity‐related complication) or obesity (BMI ≥ 30 kg/m2), without diabetes, using data ...
Wojciech Michalak   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy